Evidence map›Paper›PMID 36053592›Full record

ArticleBMJ paediatrics open2022

COVID-19 in Portugal: a retrospective review of paediatric cases, hospital and PICU admissions in the first pandemic year.

Cecilia Elias, Rodrigo Feteira-Santos, Catarina Camarinha, Miguel de Araújo Nobre, Andreia Silva Costa, Leonor Bacelar-Nicolau, Cristina Furtado, Paulo Jorge Nogueira

Open access · diamondAbstract read
In one paragraph

Article in BMJ paediatrics open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Cecilia EliasEPI Task-Force FMUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal cecilia.elias@proton.me.ORCID 0000-0002-3922-7152
Rodrigo Feteira-SantosEPI Task-Force FMUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.ORCID 0000-0002-5780-2288
Catarina CamarinhaEPI Task-Force FMUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Miguel de Araújo NobreEPI Task-Force FMUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.ORCID 0000-0002-7084-8301
Andreia Silva CostaEPI Task-Force FMUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.ORCID 0000-0002-2727-4402
Leonor Bacelar-NicolauEPI Task-Force FMUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.ORCID 0000-0003-0421-1262
Cristina FurtadoEPI Task-Force FMUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.ORCID 0000-0003-2632-0945
Paulo Jorge NogueiraEPI Task-Force FMUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.ORCID 0000-0001-8316-5035
University of Lisbon · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 is considered by WHO a pandemic with public health emergency repercussions. Children often develop a mild disease with good prognosis and the recognition of children at risk is essential to successfully manage paediatric COVID-19. Quality epidemiological surveillance data are required to characterise and assess the pandemic.

methodsData on all reported paediatric COVID-19 cases, in Portugal, were retrospectively assessed from a fully anonymised dataset provided by the Directorate General for Health (DGS). Paediatric hospital admission results were obtained from the DGS vaccine recommendations and paediatric intensive care unit (PICU) admission results from the EPICENTRE.PT group. Reported cases and PICU admissions from March 2020 to February 2021 and hospital admissions between March and December 2020 were analysed.

results92 051 COVID-19 cases were studied, 50.5% males, average age of 10.1 years, corresponding to 5.4% of children in Portugal. The most common symptoms were cough and fever, whereas gastrointestinal symptoms were infrequent. The most common comorbidity was asthma. A high rate of missing surveillance data was noticed, on presentation of disease and comorbidity variables, which warrants a cautious interpretation of results. Hospital admission was required in 0.93% of cases and PICU on 3.48 per 10 000 cases. PICU admission for Multisystem Inflammatory Syndrome in Children (MIS-C) was more frequent in children with no comorbidities and males, severe COVID-19 was rarer and occurred mainly in females and infants. Case fatality rate and mortality rates were low, 1.8 per 100 000 cases and 1.2 per 1 000 000 cases, respectively.

conclusionsThe overall reported case incidence was 5.4 per 100 children and adolescents and <1% of cases required hospital admission. MIS-C was more frequent in patients with no comorbidities and males. Mortality and case fatality rates were low. Geographic adapted strategies, and information systems to facilitate surveillance are required to improve surveillance data quality.

Indexed as

COVID-19PandemicsAdolescentChildFemaleHospitalsHumansInfantIntensive Care Units, PediatricMalePortugalRetrospective StudiesSystemic Inflammatory Response SyndromeCOVID-19epidemiologymortality

Identifiers

PMID36053592
PMCPMC9438012
OpenAlexW4293457253

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.